A Study of Dapagliflozin in Chinese Adult Patients With Chronic Kidney Disease

Inclusion Criteria:

• Provision of signed informed consent prior to any study specific procedures

• Chinese Female or male aged ≥ 18 years at the time of consent

• eGFR ≥ 25 and ≤ 75 mL/min/1.73m2 (CKD-EPI Formula) at visit 1

• Evidence of increased albuminuria 3 months or more before visit 1 and UACR ≥ 200 and ≤ 5000 mg/g at visit 1

• Stable, and for the patient maximum tolerated labelled daily dose, treatment withACE-I or ARB for at least 4 weeks before visit 1, if not medically contraindicated

Exclusion Criteria:

• Autosomal dominant or autosomal recessive polycystic kidney disease, lupus nephritisor anti-neutrophil cytoplasmic antibodies-associated vasculitis

• Receiving cytotoxic therapy, immunosuppressive therapy or other immunotherapy forprimary or secondary renal disease within 6 months prior to enrolment

• History of organ transplantation

• Receiving therapy with an SGLT2 inhibitor within 8 weeks prior to enrolment orprevious intolerance of an SGLT2 inhibitor

• T1DM

• New York Heart Association class IV Congestive Heart Failure at the time ofenrolment

• MI, unstable angina, stroke or TIA within 12 weeks prior to enrolment

• Coronary revascularization (PCI or CABG) or valvular repair/replacement within 12weeks prior to enrolment

• Any condition outside the renal and CV disease area, such as but not limited tomalignancy, with a life expectancy of less than 2 years based on investigator´sclinical judgement

• Active malignancy requiring treatment at the time of visit 1 (with the exception ofsuccessfully treated basal cell or treated squamous cell carcinoma)

• Hepatic impairment (AST or ALT > 3 × ULN; or total bilirubin > 2 × ULN at time ofenrolment). An solated increase in bilirubin in patients with known Gilbert'ssyndrome is not a reason for exclusion

• Known blood-borne diseases

• Women of child-bearing potential (ie, those who are not chemically or surgicallysterilised or who are not post-menopausal) who are not willing to use a medicallyaccepted method of contraception that is considered reliable in the judgment of theinvestigator, from the time of signing the informed consent throughout the study and 4 weeks thereafter, OR women who have a positive pregnancy test at enrolment ORwomen who are breast-feeding

• Involvement in the planning and/or conduct of the study (applies to both AstraZenecapersonnel and/or site personnel)

• Previous enrolled in the present study

• Participation in another clinical study with a study intervention during the lastmonth prior to enrolment

• Inability of the patient, in the opinion of the investigator, to understand and/orcomply with study intervention, procedures and/or follow-up OR any conditions that,in the opinion of the investigator, may render the patient unable to complete thestudy